Latin America, As a Whole, Refuses to Embrace Total Economic War Against Russia
Tag: Pfizer
The Pfizer Documents
On YouTube: Dr. John Campbell goes over the Pfizer documents of adverse reactions to the jab. (More sources in description)
Sources:
A Midwestern Doctor: Adverse Reactions to COVID Vaccines I Have Come Across
UPDATED: FDA is considering FOURTH dose of COVID-19 vaccine and making it an annual shot as cases across the US drop 43% over the past week and 87% since the peak of the Omicron variant
Related:
WSJ: FDA Eyes Second Covid-19 Booster Shot
A fourth booster shot of either the Pfizer or Moderna vaccine could start an annual booster shot campaign, one of the people familiar with the FDA’s planning said.
I’m not buying the media’s scaremongering about the second omicron variant!
How Bannon’s “Billionaire” BFF Built an Empire of Bullshit
The weird, wild, and scary tale of Miles Guo. (Archived).
A Fugitive Chinese Tycoon Met Steve Bannon. Misinformation Mayhem Ensued.
Related:
Omicron-targeted vaccines do no better than original jabs in early tests
Pfizer drops India vaccine application after regulator seeks local trial
J&J pauses production of its Covid-19 vaccine despite persistent need 💰
J&J pauses production of its Covid-19 vaccine despite persistent need
The facility, in the Dutch city of Leiden, has instead been making an experimental but potentially more profitable vaccine to protect against an unrelated virus.
…
But poorer countries remain reliant on Johnson & Johnson’s vaccine, which does not require ultracold refrigeration. It has been shown to provide strong and long-lasting protection against severe disease across variants, including omicron, when given as a two-shot regimen. As a single shot, the vaccine is less expensive and relatively easy to give to hard-to-reach populations.
…
Unlike companies such as Pfizer and Moderna, which have reaped billions of dollars in profits, Johnson & Johnson did not find the COVID vaccine to be a big moneymaker.
….
Since production of the COVID vaccine was halted late last year, the Netherlands plant has been manufacturing an experimental vaccine against respiratory syncytial virus, or RSV, that will be used for a clinical trial in older adults in wealthy countries, a person familiar with the matter said. Even if it proves effective, the vaccine is not expected to become available for several years.

You must be logged in to post a comment.